WO2002018593A3 - Modulation de l'expression de fas et de fasl - Google Patents

Modulation de l'expression de fas et de fasl Download PDF

Info

Publication number
WO2002018593A3
WO2002018593A3 PCT/CA2001/000845 CA0100845W WO0218593A3 WO 2002018593 A3 WO2002018593 A3 WO 2002018593A3 CA 0100845 W CA0100845 W CA 0100845W WO 0218593 A3 WO0218593 A3 WO 0218593A3
Authority
WO
WIPO (PCT)
Prior art keywords
modulation
fas
fasl expression
efficacy
modulate
Prior art date
Application number
PCT/CA2001/000845
Other languages
English (en)
Other versions
WO2002018593A2 (fr
Inventor
Nigel C Phillips
Mario C Filion
Original Assignee
Bioniche Life Sciences Inc
Nigel C Phillips
Mario C Filion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CA2000/001467 external-priority patent/WO2001044465A2/fr
Priority to ES01947067T priority Critical patent/ES2383671T3/es
Priority to JP2002522500A priority patent/JP2004507469A/ja
Priority to EP01947067A priority patent/EP1313853B1/fr
Priority to AT01947067T priority patent/ATE550428T1/de
Priority to CA002420103A priority patent/CA2420103A1/fr
Application filed by Bioniche Life Sciences Inc, Nigel C Phillips, Mario C Filion filed Critical Bioniche Life Sciences Inc
Priority to AU2001268863A priority patent/AU2001268863B2/en
Priority to DK01947067.3T priority patent/DK1313853T3/da
Priority to MXPA03001812A priority patent/MXPA03001812A/es
Priority to AU6886301A priority patent/AU6886301A/xx
Publication of WO2002018593A2 publication Critical patent/WO2002018593A2/fr
Publication of WO2002018593A3 publication Critical patent/WO2002018593A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)

Abstract

La présente invention concerne un procédé faisant intervenir l'utilisation d'une composition comprenant de 2 à 10 séquences oligonucléotidiques synthétiques de base choisies parmi le groupe comprenant (GG)n, (GT)n, a(GT)nb, a(GA)nb, et a(GC)nb, où n est un entier de 1 à 3, et a et b sont indépendamment zéro, un ou plusieurs des éléments As, Cs, Gs, ou Ts, ou de leurs combinaisons, ladite composition étant utilisée pour moduler l'expression de Fas et de FasL ou pour moduler l'efficacité d'agents thérapeutiques. La composition est administrée à un animal ou à un être humain avec un excipient pharmaceutiquement acceptable, et éventuellement avec un agent thérapeutique, en une quantité efficace pour moduler l'expression de Fas et de FasL, pour traiter la maladie, ou pour moduler l'efficacité de l'agent thérapeutique.
PCT/CA2001/000845 1999-12-13 2001-06-12 Modulation de l'expression de fas et de fasl WO2002018593A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU6886301A AU6886301A (en) 2000-08-29 2001-06-12 Modulation of fas and fasl expression
JP2002522500A JP2004507469A (ja) 2000-08-29 2001-06-12 Ｆａｓおよびｆａｓｌ発現の調整
EP01947067A EP1313853B1 (fr) 2000-08-29 2001-06-12 Modulation de l'expression de fas et fasl par un oligonucléotide phosphodiester synthétique et un anticorps anti-fas
AT01947067T ATE550428T1 (de) 2000-08-29 2001-06-12 Modulierung der fas und fasl expression durch ein synthetisches oligonukleotid und einen anti-fas antikörper
CA002420103A CA2420103A1 (fr) 2000-08-29 2001-06-12 Modulation de l'expression de fas et de fasl
ES01947067T ES2383671T3 (es) 2000-08-29 2001-06-12 Modulación de la expresión de Fas y FasL por un oligonucleótido-fosfodiéster sintético y un anticuerpo anti-Fas
AU2001268863A AU2001268863B2 (en) 1999-12-13 2001-06-12 Modulation of FAS and FASL expression
DK01947067.3T DK1313853T3 (da) 2000-08-29 2001-06-12 Modulering af Fas- og Fasl-ekspression med et syntetisk phosphodiesteroligonucleotid og et anti-Fas-antistof
MXPA03001812A MXPA03001812A (es) 2000-08-29 2001-06-12 Modulacion de la expresion del sindrome de alcohol fetal y del ligando del sindrome de alcohol fetal..

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US22892500P 2000-08-29 2000-08-29
US60/228,925 2000-08-29
US09/735,363 2000-12-12
CAPCT/CA00/01467 2000-12-12
PCT/CA2000/001467 WO2001044465A2 (fr) 1999-12-13 2000-12-12 Oligonucleotides synthetiques utiles du point de vue therapeutique
US09/735,363 US7157436B2 (en) 1999-12-13 2000-12-12 Therapeutically useful synthetic oligonucleotides
US26622901P 2001-02-02 2001-02-02
US60/266,229 2001-02-02

Publications (2)

Publication Number Publication Date
WO2002018593A2 WO2002018593A2 (fr) 2002-03-07
WO2002018593A3 true WO2002018593A3 (fr) 2002-12-12

Family

ID=27426776

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2001/000845 WO2002018593A2 (fr) 1999-12-13 2001-06-12 Modulation de l'expression de fas et de fasl

Country Status (6)

Country Link
EP (1) EP1313853B1 (fr)
JP (1) JP2004507469A (fr)
AU (1) AU6886301A (fr)
CA (1) CA2420103A1 (fr)
MX (1) MXPA03001812A (fr)
WO (1) WO2002018593A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087586B2 (en) * 2001-04-24 2006-08-08 Bioniche Life Sciences, Inc. Oligonucleotide compositions and their use to induce differentiation of cells

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008053A1 (fr) * 1992-09-29 1994-04-14 Isis Pharmaceuticals, Inc. Oligonucleotides possedant une sequence noyau g4 conservee
WO1996023508A1 (fr) * 1995-01-31 1996-08-08 Board Of Regents Of The University Of Nebraska Oligonucleotides synthetiques imitant des sequences telomeriques
WO1997020924A1 (fr) * 1995-12-04 1997-06-12 Saicom S.R.L Classe d'oligonucleotides, utiles du point de vue therapeutique comme agents anti-tumoraux
WO1999003998A1 (fr) * 1997-07-17 1999-01-28 The Regents Of The University Of Michigan Procedes et compositions servant a reduire une tumeur
WO2001044465A2 (fr) * 1999-12-13 2001-06-21 Bioniche Life Sciences Inc. Oligonucleotides synthetiques utiles du point de vue therapeutique

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008053A1 (fr) * 1992-09-29 1994-04-14 Isis Pharmaceuticals, Inc. Oligonucleotides possedant une sequence noyau g4 conservee
WO1996023508A1 (fr) * 1995-01-31 1996-08-08 Board Of Regents Of The University Of Nebraska Oligonucleotides synthetiques imitant des sequences telomeriques
WO1997020924A1 (fr) * 1995-12-04 1997-06-12 Saicom S.R.L Classe d'oligonucleotides, utiles du point de vue therapeutique comme agents anti-tumoraux
WO1999003998A1 (fr) * 1997-07-17 1999-01-28 The Regents Of The University Of Michigan Procedes et compositions servant a reduire une tumeur
WO2001044465A2 (fr) * 1999-12-13 2001-06-21 Bioniche Life Sciences Inc. Oligonucleotides synthetiques utiles du point de vue therapeutique

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MORASSUTTI C ET AL: "CORRELATION BETWEEN CYTOTOXIC EFFECT AND BINDING TO NUCLEAR PROTEINS OF OLIGOMERIC D(GT)N SEQUENCES IN HUMAN CANCER CCRF-CEM CELL LINE", MINERVA BIOTECNOLOGICA, vol. 7, no. 2, 1 June 1995 (1995-06-01), pages 176 - 181, XP000671788, ISSN: 1120-4826 *
READER S ET AL: "IDENTIFICATION OF NON-ANTISENSE PHOSPHODIESTER OLIGONUCLEOTIDES THAT INDUCE CELL CYCLE ARREST AND APOPTOSIS IN CANCER CELLS", CLINICAL CANCER RESEARCH, vol. 6, no. SUPPL, 2000, pages 526, XP001002269, ISSN: 1078-0432 *
SCAGGIANTE BRUNA ET AL: "Human cancer cell lines growth inhibition by GTn oligodeoxyribonucleotides recognizing single-stranded DNA-binding proteins", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 252, no. 2, 1 March 1998 (1998-03-01), pages 207 - 215, XP002168739, ISSN: 0014-2956 *
SOLARY ERIC ET AL: "Role of the Fas/Fas-L system in the immune response to tumors and the resistance to cytotoxic drugs.", BULLETIN DU CANCER (PARIS), vol. 85, no. 8, August 1998 (1998-08-01), pages 685 - 694, XP008008873, ISSN: 0007-4551 *

Also Published As

Publication number Publication date
AU6886301A (en) 2002-03-13
MXPA03001812A (es) 2004-05-21
EP1313853A2 (fr) 2003-05-28
WO2002018593A2 (fr) 2002-03-07
CA2420103A1 (fr) 2002-03-07
EP1313853B1 (fr) 2012-03-21
JP2004507469A (ja) 2004-03-11

Similar Documents

Publication Publication Date Title
IL264560B (en) Preparations for improved activity to kill mites
EP1707563A3 (fr) Procedes et compositions utilisant des quinazolinones
EP1810715A3 (fr) Combinaison comprenant un agent pour diminuer l'activité du VEGF et un agent pour diminuer l'activité du EGF
WO2001033966A3 (fr) Combinaison de substances actives a proprietes insecticides et acaricides
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
EP2174662A3 (fr) Procédés pour traiter les blessures musculaires
EP1248791A4 (fr) Modulation anti-sens de l'expression de la caspase 3
ES2031096T3 (es) Una composicion de implante mejorada a base de estradiol y metodo para su preparacion.
MX337223B (es) Mezcla insecticida que contiene gamma-cihalotrina.
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
DE60043587D1 (de) Mittel für erkrankungen assoziert mit knochensubstanzverlust
WO1999004772A3 (fr) Levobupivacine et son utilisation
WO2004032840A3 (fr) Composes, compositions et methodes
WO1999061014A3 (fr) Compositions et methodes utilisant de la r(-) fluoxetine et d'autres ingredients actifs
ZA200201807B (en) Active ingredient combinations having insecticidal and acaricidal properties.
WO2002043757A3 (fr) Medicament pour la prophylaxie ou le traitement de tumeurs induites par le virus du papillome humain de type 18
WO2002018593A3 (fr) Modulation de l'expression de fas et de fasl
EP0958835A4 (fr) Remede therapeutique ou preventif contre l'incontinence ou l'elimination urinaire frequente
NO941097D0 (no) Hudregenererende kosmetisk preparat
WO2004032879A3 (fr) Composes, compositions et procedes
EP1390388A4 (fr) Modulation antisens de l'expression du recepteur 1 de l'interferon gamma
WO2002040637A3 (fr) Modulation antisens de l'expression de pi3k p85
EP1397516A4 (fr) Modulation antisens de l'expression de la sous-unite p40 de l'interleukine 12
YU51198A (sh) 1,4 diaril-2,3-difluor-2-buten insekticidni i akaricidni agensi
WO1999033454A3 (fr) Procyclidine-s aux fins du traitement de l'incontinence urinaire

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2420103

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001268863

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/001812

Country of ref document: MX

Ref document number: 2002522500

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001947067

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001947067

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2001268863

Country of ref document: AU